Trial · NCT03586284
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
NCT03586284, Phase 2, Phase 3, Terminated, University of California, San Francisco; results first posted 2026-02-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes. Trials, record NCT03586284. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03586284
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes
- NCT number
- NCT03586284
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 51 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Cytomegalovirus Anterior Uveitis
- Interventions
- Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo
- First posted
- 2018-07-13
- Last updated
- 2026-03-05
- Results first posted
- 2026-02-10
- Limitations and caveats
Small sample and early stopping limited power. Baseline imbalances (e.g., prostaglandin use, viral load) required multivariable adjustment. The 7-day endpoint assesses early antiviral activity and does not address durability, recurrence, or long-term IOP control. Variable aqueous volume made low-end quantitation imprecise; values below the assay's LLOQ were treated as non-quantifiable and set to the LLOQ for analysis. Inference emphasizes adjusted between-arm contrasts.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in CMV Viral Load | 7 days | Pre-treatment minus day-7 CMV DNA load in aqueous humor, reported as log10 IU/mL (WHO-standardized qPCR). Positive values indicate reduction. |
| Secondary | Number of Participants That Achieved Clinical Quiescence | Day 0 to Day 21 (final visit) | Comparison between arms of percent that achieved clinical quiescence by final visit (anterior chamber cell ≤ 0.5+). |
| Secondary | Effect of Topical Corticosteroid | Day 0 (pre-treatment) viral load (IU/mL) | What effect did topical corticosteroid use prior to enrollment have on pre-treatment viral load (Day 0) |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in CMV Viral Load | 7 days | Includes randomized participants with paired baseline and day-7 aqueous qPCR results (oral 19/19, topical 13/13, placebo 15/15). | log10 IU/mL | MEAN |
| SECONDARY | Number of Participants That Achieved Clinical Quiescence | Day 0 to Day 21 (final visit) | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Effect of Topical Corticosteroid | Day 0 (pre-treatment) viral load (IU/mL) | IU/mL | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in CMV Viral Load | Oral Valganciclovir | 0.59 | Standard Deviation 0.87 | log10 IU/mL | |
| Change in CMV Viral Load | Topical Ganciclovir 2% | 0.23 | Standard Deviation 0.59 | log10 IU/mL | |
| Change in CMV Viral Load | Placebo | 0.04 | Standard Deviation 0.44 | log10 IU/mL | |
| Number of Participants That Achieved Clinical Quiescence | Oral Valganciclovir | 19 | Participants | ||
| Number of Participants That Achieved Clinical Quiescence | Topical Ganciclovir 2% | 13 | Participants | ||
| Number of Participants That Achieved Clinical Quiescence | Placebo | 15 | Participants | ||
| Effect of Topical Corticosteroid | Oral Valganciclovir | 0.10 | 95% Confidence Interval -0.06 to 0.26 | IU/mL | |
| Effect of Topical Corticosteroid | Topical Ganciclovir 2% | 0.10 | 95% Confidence Interval -0.06 to 0.26 | IU/mL | |
| Effect of Topical Corticosteroid | Placebo | 0.10 | 95% Confidence Interval -0.06 to 0.26 | IU/mL |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oral Valganciclovir | 19 | |
| Overall Study | STARTED | Topical Ganciclovir 2% | 15 | |
| Overall Study | STARTED | Placebo | 17 | |
| Overall Study | COMPLETED | Oral Valganciclovir | 19 | |
| Overall Study | COMPLETED | Topical Ganciclovir 2% | 13 | |
| Overall Study | COMPLETED | Placebo | 15 | |
| Overall Study | NOT COMPLETED | Oral Valganciclovir | 0 | |
| Overall Study | NOT COMPLETED | Topical Ganciclovir 2% | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oral Valganciclovir | 0 | 19 |
| Total, all-cause mortality | Topical Ganciclovir 2% | 0 | 15 |
| Total, all-cause mortality | Placebo | 0 | 13 |
| Total, other adverse events | Oral Valganciclovir | 0 | 19 |
| Total, other adverse events | Topical Ganciclovir 2% | 0 | 15 |
| Total, other adverse events | Placebo | 0 | 13 |
| Total, serious adverse events | Oral Valganciclovir | 0 | 19 |
| Total, serious adverse events | Topical Ganciclovir 2% | 0 | 15 |
| Total, serious adverse events | Placebo | 0 | 13 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 31862739 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03586284
GET https://conductscience.org/api/trials/v1/NCT03586284/registered